JAMES R TOBIN
CIK 1190128 · President & CEO · last filed 2026-05-22
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$41.37M
Companies
9
Total Filings
92
Lifetime Open-Market Net
-$20.75M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| TMDX | Director | 162,127 | $80.21 | $13.00M | -$14.29M | 20 | 2026-05-22 |
| GMED | Director | 5,308 | $81.08 | $430.4K | -$6.43M | 18 | 2026-01-23 |
| Lyra Therapeutics, Inc. (LYRA) Delisted | Director | — | $0.70 | — | $0 | 4 | 2025-05-16 |
| Oxford Immunotec Global PLC (OXFD) Delisted | Director | 4,081 | — | — | $0 | 7 | 2020-06-26 |
| Corindus Vascular Robotics, Inc. (CVRS) Delisted | Director | 106,112 | — | — | $0 | 9 | 2019-10-09 |
| CHIASMA, INC (CHMA) Delisted | Director | — | $3.76 | — | $0 | 2 | 2016-06-13 |
| CRIS | Director | 72 | $4.41 | $318 | -$39.2K | 13 | 2015-01-28 |
| BSX | President & CEO | 566,550 | $49.30 | $27.93M | $0 | 4 | 2009-02-26 |
| APPLIED BIOSYSTEMS INC. (CRA) Delisted | Director | 0 | — | — | $0 | 7 | 2008-06-04 |
Recent Filings · Page 2 of 10
92 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-05-07 | TMDX | Sell (S) | −12,025 | -$1.50M | EDGAR |
| 2024-05-03 | TMDX | Sell (S) | −15,040 | -$1.60M | EDGAR |
| 2024-05-01 | TMDX | Notice (144) | −27,065 | -$3.27M | EDGAR |
| 2024-03-05 | TMDX | Sell (S) | −13,380 | -$1.12M | EDGAR |
| 2024-03-01 | TMDX | Notice (144) | −13,380 | -$1.12M | EDGAR |
| 2024-01-30 | GMED | Grant (A) | — | $0 | EDGAR |
| 2023-11-29 | TMDX | Sell (S) | −10,000 | -$701.4K | EDGAR |
| 2023-11-28 | TMDX | Notice (144) | −10,000 | -$701.4K | EDGAR |
| 2023-07-05 | Lyra Therapeutics, Inc. (LYRA) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-05-30 | TMDX | Grant (A) | +1,193 | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.